Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering

SRRK 10.22.2024

Full Press ReleaseSEC FilingsOur SRRK Tweets

About Gravity Analytica

Recent News

  • 01.17.2025 - Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • 01.14.2025 - 43rd Annual JP Morgan Healthcare Conference
  • 01.08.2025 - Scholar Rock Highlights 2025 Strategic Priorities

Recent Filings

  • 01.21.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.14.2025 - EX-99.1 EX-99.1
  • 01.14.2025 - 8-K Current report

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 22, 2024--Scholar Rock Holding Corporation(Nasdaq: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that onOctober 16, 2024, the underwriters of its previously announced underwritten public offering of common stock and pre-funded warrants, which closed onOctober 10, 2024, exercised their option in full to purchase an additional 1,592,920 shares at the public offering price of$28.25per share, resulting in additional gross proceeds of approximately$45 million, before deducting underwriting discounts and commissions and offering expenses payable byScholar Rock. The closing of the underwriters’ exercise of their option to purchase 1,592,920 additional shares occurred onOctober 18, 2024.

J.P. Morgan Securities LLC, Jefferies andPiper Sandler & Co.acted as joint book-running managers for the offering.BMO Capital Markets Corp.,Wedbush Securities Inc.andRaymond James & Associates, Inc.acted as co-managers for the offering.

An automatically effective shelf registration statement on Form S-3 relating to the offering of the shares of common stock and pre-funded warrants described above was filed with theSecurities and Exchange Commission(SEC) onOctober 7, 2024. A preliminary prospectus supplement and accompanying prospectus relating to the offering were filed with theSEConOctober 7, 2024, and are available on the SEC’s website located atwww.sec.gov. The final prospectus supplement and accompanying prospectus relating to the offering were filed with theSEConOctober 9, 2023and may be obtained by contacting:J.P. Morgan Securities LLC, c/o: Broadridge Financial Solutions,1155 Long Island Avenue,Edgewood, NY11717, or by email atprospectus-eq_fi@jpmchase.comandpostsalemanualrequests@broadridge.com;Jefferies LLC, Attention:Equity Syndicate Prospectus Department,520 Madison Avenue,New York, NY10022, by telephone at 877-821-7388, or by email atprospectus_department@jefferies.com; orPiper Sandler & Co.,800 Nicollet Mall, J12S03,Minneapolis, MN55402, Attention: Prospectus Department, by telephone at 800-747-3924, or by email atprospectus@psc.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

AboutScholar Rock

Scholar Rockis a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade,Scholar Rockhas created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role.

This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies,Scholar Rockworks every day to create new possibilities for patients.

Scholar Rock®is a registered trademark ofScholar Rock, Inc.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241022036032/en/

Scholar Rock:InvestorsRushmie NofsingerScholar Rockrnofsinger@scholarrock.comir@scholarrock.com857-259-5573

MediaMolly MacLeodScholar Rockmmacleod@scholarrock.commedia@scholarrock.com802-579-5995

Source:Scholar Rock

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com